Drug Trial Radar · NCT07563010
Menin-Inhibitor Targeted Maintenance in AML
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2031
Study completion Jun 2031
Sponsor
- Lead sponsor
- Center for International Blood and Marrow Transplant ResearchResearch network
- Sponsor type
- Research network
- Collaborators
- National Marrow Donor Program; Dana-Farber Cancer Institute
- First posted
- May 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.
Conditions
- Relapsed Adult AML
- Stem Cell Transplant Complications
- Acute Myeloid Leukemia
- Transplant-Related Hematologic Malignancy
Interventions
RevumenibDrug
oral tablets
PlaceboDrug
oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse free survival (RFS) in KMT2Ar, NPM1m, and NUP98r AML in the Intent-to-Treat (ITT) population with a minimum of 1 year of follow-up post-randomization.Time frame: From randomization to the date of event occurrence, assessed for a minimum of 1 year post-randomization.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.